Immvention Therapeutix Inc. has entered into a collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease and other chronic conditions.
Immvention Therapeutix Inc. has disclosed benzimidazole-containing compounds acting as inflammasome inhibitors reported to be useful for the treatment of inflammatory disorders.
